title: Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer.
abstract: Lung cancer remains incurable in many cases despite current chemotherapies. We explored an approach combining a recently described antiangiogenic drug, rapamycin, with standard docetaxel cytotoxic therapy on the growth of non-small-cell lung cancer. Rapamycin alone inhibited tumor growth and upregulated apoptosis, with more pronounced effects when rapamycin and docetaxel were combined. Tumor vessel endothelium damage and thrombosis was evident with rapamycin treatment; this was concomitant with decreased microvessel density. In contrast, docetaxel was not antiangiogenic and did not reduce proliferation in tumors, despite its known cytotoxicity. Our data represent a new promising therapeutic regimen against non-small-cell lung cancer.
authors: Departments of Respiratory Medicine, Nantong University, Nantong, Jiangsu, China.
authors: Liqin
authors: L
authors: Xu
authors: Yan
authors: Y
authors: Qin
authors: Jianfei
authors: J
authors: Huang
authors: Jing
authors: J
authors: Qin
authors: Jun
authors: J
authors: Gu
authors: Huijun
authors: H
authors: Zhu
authors: Hong
authors: H
authors: Liu
authors: Yifeng
authors: Y
authors: Cai
authors: Xinhua
authors: X
authors: Wu
authors: Jian
authors: J
authors: Feng
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D045744:Cell Line, Tumor / Q000187:drug effects / Q000637:transplantation; D000077143:Docetaxel; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D019394:Ki-67 Antigen / Q000032:analysis; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D055806:Microvessels / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D020123:Sirolimus / Q000008:administration & dosage / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms; D043823:Taxoids / Q000008:administration & dosage; D013927:Thrombosis / Q000139:chemically induced*; D047368:Tumor Burden; D014410:Tumor Stem Cell Assay; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D019394:Ki-67 Antigen; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D043823:Taxoids; D000077143:Docetaxel; D020123:Sirolimus